Your browser doesn't support javascript.
loading
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.
Dong, Jinhui; Zost, Seth J; Greaney, Allison J; Starr, Tyler N; Dingens, Adam S; Chen, Elaine C; Chen, Rita E; Case, James Brett; Sutton, Rachel E; Gilchuk, Pavlo; Rodriguez, Jessica; Armstrong, Erica; Gainza, Christopher; Nargi, Rachel S; Binshtein, Elad; Xie, Xuping; Zhang, Xianwen; Shi, Pei-Yong; Logue, James; Weston, Stuart; McGrath, Marisa E; Frieman, Matthew B; Brady, Tyler; Tuffy, Kevin M; Bright, Helen; Loo, Yueh-Ming; McTamney, Patrick M; Esser, Mark T; Carnahan, Robert H; Diamond, Michael S; Bloom, Jesse D; Crowe, James E.
  • Dong J; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Zost SJ; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Greaney AJ; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Starr TN; Department of Genome Sciences & Medical Scientist Training Program, University of Washington, Seattle, WA, USA.
  • Dingens AS; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Chen EC; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Chen RE; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Case JB; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Sutton RE; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Gilchuk P; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Rodriguez J; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Armstrong E; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Gainza C; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Nargi RS; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Binshtein E; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Xie X; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Zhang X; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Shi PY; Department of Biochemistry & Molecular Biology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.
  • Logue J; Department of Biochemistry & Molecular Biology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.
  • Weston S; Department of Biochemistry & Molecular Biology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.
  • McGrath ME; Department of Microbiology and Immunology, The University of Maryland, College Park, MD, USA.
  • Frieman MB; Department of Microbiology and Immunology, The University of Maryland, College Park, MD, USA.
  • Brady T; Department of Microbiology and Immunology, The University of Maryland, College Park, MD, USA.
  • Tuffy KM; Department of Microbiology and Immunology, The University of Maryland, College Park, MD, USA.
  • Bright H; Microbial Sciences, AstraZeneca, Gaithersburg, MD, USA.
  • Loo YM; Microbial Sciences, AstraZeneca, Gaithersburg, MD, USA.
  • McTamney PM; Microbial Sciences, AstraZeneca, Gaithersburg, MD, USA.
  • Esser MT; Microbial Sciences, AstraZeneca, Gaithersburg, MD, USA.
  • Carnahan RH; Microbial Sciences, AstraZeneca, Gaithersburg, MD, USA.
  • Diamond MS; Microbial Sciences, AstraZeneca, Gaithersburg, MD, USA.
  • Bloom JD; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Crowe JE; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Nat Microbiol ; 6(10): 1233-1244, 2021 10.
Article en En | MEDLINE | ID: mdl-34548634
ABSTRACT
Understanding the molecular basis for immune recognition of SARS-CoV-2 spike glycoprotein antigenic sites will inform the development of improved therapeutics. We determined the structures of two human monoclonal antibodies-AZD8895 and AZD1061-which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor-binding domain (RBD) of SARS-CoV-2 to define the genetic and structural basis of neutralization. AZD8895 forms an 'aromatic cage' at the heavy/light chain interface using germ line-encoded residues in complementarity-determining regions (CDRs) 2 and 3 of the heavy chain and CDRs 1 and 3 of the light chain. These structural features explain why highly similar antibodies (public clonotypes) have been isolated from multiple individuals. AZD1061 has an unusually long LCDR1; the HCDR3 makes interactions with the opposite face of the RBD from that of AZD8895. Using deep mutational scanning and neutralization escape selection experiments, we comprehensively mapped the crucial binding residues of both antibodies and identified positions of concern with regards to virus escape from antibody-mediated neutralization. Both AZD8895 and AZD1061 have strong neutralizing activity against SARS-CoV-2 and variants of concern with antigenic substitutions in the RBD. We conclude that germ line-encoded antibody features enable recognition of the SARS-CoV-2 spike RBD and demonstrate the utility of the cocktail AZD7442 in neutralizing emerging variant viruses.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / SARS-CoV-2 Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / SARS-CoV-2 Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article